Evidence map›Paper›PMID 39926581›Full record

ArticleEuropean journal of case reports in internal medicine2025

Adalimumab-Induced Optic Neuropathy in A Patient with Behçet's Syndrome.

Sofia Miranda, Daniel Calado, Joana Rua, Fernando Salvador

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sofia MirandaInternal Medicine Department, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal.
Daniel CaladoInternal Medicine Department, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal.
Joana RuaInternal Medicine Department, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal.
Fernando SalvadorInternal Medicine Department, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 37-year-old woman with a diagnosis of Behçet's syndrome, treated with colchicine and prednisolone, maintained low disease activity for a period of 10 years, after which, she developed a new episode of anterior uveitis. A cycle of high dose systemic corticosteroids was required but the patient presented with a new flare during dose tapering. A decision to initiate a corticosteroid-sparing agent was then made, with an initially satisfactory response. However, 3 months later the ocular symptoms recurred, and a new bout of oral ulceration appeared concurrently. As a result, adalimumab was then started, but the patient presented with a sudden and severe decrease of visual acuity in her right eye 4 months later. The initial bloodwork showed no elevated inflammatory markers. A lumbar puncture showed a normal cerebrospinal fluid composition. Although these findings made it less probable that the patient's symptoms were caused by infectious or autoimmune disease, extensive investigations directed at these possible causes were performed, with negative results. Several imaging tests were also performed, which showed no alterations. However, a sensory evoked potentials test revealed a functional compromise at the pre-chiasmatic level. An iatrogenic optic neuropathy induced by adalimumab seemed the most probable cause and a decision to suspend the treatment was made. A new cycle of high dose systemic corticosteroids consisting of three pulses of methylprednisolone followed by pred-nisolone with a quick tapering over 4 weeks was also started, with gradual improvement of visual acuity. LEARNING POINTS: Albeit used for the management of ocular manifestations of systemic diseases like Behçet's syndrome, anti-tumour necrosis factor (TNF)-alpha inhibitors can paradoxically be associated with ocular adverse effects.Optic neuritis is one of the possible ocular adverse effects although rarer than anterior uveitis.Iatrogenic optic neuritis due to anti-TNFα inhibitors remains a diagnosis of exclusion but should be kept in mind.

Indexed as

Adalimumaboptic neuropathy

Identifiers

PMID39926581
PMCPMC11801509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.